Rossijskij Bioterapevticeskij Zurnal

Aims & Scope

Main objectives of the Journal are: consolidation of scientific and practical achievements in the field of drug therapy of immunological and oncological diseases.

Scientific concept of the Journal suggests publication of current achievements in the field of drug therapy of immunological and oncological diseases, results of the research studies, results of national and international pre-clinical and clinical studies.

The Journal invites both national and international authors – scientists and doctors who work in oncology and other relevant areas.

The Journal presents results of the studies of new biomarkers of oncological and immune diseases, the use of biomarkers in diagnostics and therapy of tumors and disorders of the immune system, studies in the field of drug therapy, studies of drug development technologies, pre-clinical and clinical studies of new drugs and methods of treatment.

The Journal publishes materials of the annual scientific practical conference with international participation "National Anti-Tumor Drugs ", as well as announcements of Russian and International symposiums, conferences, and congresses in oncology .

View Aims & Scope

---

Metrics & Ranking

SJR (SCImago Journal Rank)

Year	Value
2024	0.116

Quartile

Year	Value
2024	Q4

h-index

Year	Value
2024	6

Journal Rank

Year	Value
2024	27807

Journal Citation Indicator

Year	Value
2024	24

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• DIsseminated tumor cells of luminal breast cancer patients .

  Citation: 14

  Authors: D. A., O. A., I. A., I. K., D. A., S. V., O. A., N. N.

• Immunodeficient mice balb/c nude and modeling of various types of tumor growth for preclinical studies

  Citation: 13

  Authors: H. M.

• THE PROSPECTS FOR THE USE OF microRNA AS DIAGNOSTIC AND PROGNOSTIC MELANOMA BIOMARKERS

  Citation: 11

  Authors: S. V., D. A., I. A., A. M., A. V., K. S., M. N., I. A., Z. M., N. V., N. N.

• Iron metabolism, ferroptosis and cancer

  Citation: 10

  Authors: A. A.

• PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART I. GENERAL NOTIONS OF PAPILLOMAVIRUSES. HUMAN PAPILLOMAVIRUSES-ASSOCIATED CANCERS

  Citation: 10

  Authors: G. M.

• Signaling TLR/RLR-mechanisms of immunomodulating action of ingavirin and thymogen preparations

  Citation: 10

  Authors: T. M., V. V., A. N., O. S., Z. A.

• TECHNOLOGICAL APPROACHES TO IMPROVING THE PROCESS LYOPHILIZATION OF PROTEIN AND PEPTIDE DRUGS

  Citation: 9

  Authors: E. V., S. V., K. V.

• LIPOSOMES AS A TARGETED DELIVERY SYSTEM OF DRUGS (REVIEW)

  Citation: 9

  Authors: V. S., Z. S., Z. M., V. G.

• PHYTOADAPTOGENS IN THE TUMOURS BIOTHERAPY AND GERIATRICS (PART 1)

  Citation: 8

  Authors: O. A., R. V., E. V., A. A., M. A., I. V., V. G., M. V.

• DEVELOPMENT AND VALIDATION OF CYPHETRYLIN ASSAY IN TABLETS

  Citation: 8

  Authors: Z. S., E. V., I. V., N. A., L. I.

---